Mephenesin can produce hemolysis leading to hemoglobinuria with intravenous administration of concentrations greater than 10% A32760. As a central nervous system depressant it can also produce paralysis and respiratory depression.
Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression A32760. It first entered use in the 1950s.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyclobenzaprine | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mephenesin. |
| Metoclopramide | The risk or severity of sedation can be increased when Metoclopramide is combined with Mephenesin. |
| Lasmiditan | The risk or severity of adverse effects can be increased when Lasmiditan is combined with Mephenesin. |
| Tramadol | The risk or severity of CNS depression can be increased when Mephenesin is combined with Tramadol. |
| Ziprasidone | The risk or severity of adverse effects can be increased when Mephenesin is combined with Ziprasidone. |
| Haloperidol | The risk or severity of CNS depression can be increased when Haloperidol is combined with Mephenesin. |
| Fluoxetine | Mephenesin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
| Oliceridine | The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Mephenesin is combined with Oliceridine. |
| Ropeginterferon alfa-2b | The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Mephenesin. |
| Daridorexant | The risk or severity of CNS depression can be increased when Mephenesin is combined with Daridorexant. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Mephenesin. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Mephenesin. |
| Midazolam | The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Mephenesin. |
| Ganaxolone | The risk or severity of sedation, somnolence, and CNS depression can be increased when Mephenesin is combined with Ganaxolone. |
| Zuranolone | The risk or severity of CNS depression can be increased when Zuranolone is combined with Mephenesin. |
| DaxibotulinumtoxinA | Mephenesin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |